SLLK, Control Peptide for TSP1 Inhibitor(TFA)

Research use only, not for human use.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.(In Vivo):Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice.TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). MRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides.

——

——

——

Others

Other Targets

——

——

——

——

573.6

C23H42F3N5O8

>98% (HPLC)

H2O : 135 mg/mL (235.36 mM; Need ultrasonic)

——

Sequence:Ser-Leu-Leu-Lys-NH2

(-20℃)

With Ice Pack

≥ 2 years